Cargando…

Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults

BACKGROUND: Adjuvanted herpes zoster (HZ) subunit (HZ/su) vaccine is recommended for healthy adults aged ≥50 years, yet vaccine efficacy is expected to wane over time. Age-sex specific cost-effectiveness analyses of HZ/su vaccine are warranted to inform decision-making on vaccine policy. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Joyce H. S., Ming, Wai-kit, Tsang, Owen Tak-yin, Chan, Paul Kay-sheung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319773/ https://www.ncbi.nlm.nih.gov/pubmed/30608953 http://dx.doi.org/10.1371/journal.pone.0210005

Ejemplares similares

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia
por: Carpenter, Christopher, et al.
Publicado: (2017)

A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia
por: Carpenter, Christopher F, et al.
Publicado: (2019)

Cost-Effectiveness of Herpes Zoster Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines
por: de Boer, Pieter T., et al.
Publicado: (2018)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
por: Grupping, Katrijn, et al.
Publicado: (2017)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Herpes Zoster Vaccination
por: Kim, Kyung Hoon
Publicado: (2013)

Herpes Zoster Vaccines
por: Harbecke, Ruth, et al.
Publicado: (2021)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
por: Giannelos, Nikolaos, et al.
Publicado: (2022)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile
por: Brosio, Federica, et al.
Publicado: (2018)

Herpes zoster vaccine in Korea
por: Choi, Won Suk
Publicado: (2013)

Vaccine against herpes zoster
por: Pasternak, Jacyr
Publicado: (2013)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine
por: Fochesato, Michel, et al.
Publicado: (2016)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper
por: García, José María Molero, et al.
Publicado: (2023)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Herpes zoster after COVID vaccination
por: van Dam, C.S., et al.
Publicado: (2021)

Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review
por: Meredith, Neil R., et al.
Publicado: (2022)

Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: A two-vaccine related event?
por: Vallianou, Natalia G., et al.
Publicado: (2022)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
por: Oostvogels, Lidia
Publicado: (2017)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
por: Godeaux, Olivier, et al.
Publicado: (2017)

Herpes Zoster: the rationale for the introduction of vaccination in Italy
por: PAGANINO, C., et al.
Publicado: (2015)

Update on Recommendations for Use of Herpes Zoster Vaccine
por: Hales, Craig M., et al.
Publicado: (2014)

Vaccines for preventing herpes zoster in older adults
por: Gagliardi, Ana M. Z., et al.
Publicado: (2014)

Effectiveness of Live Zoster Vaccine in Preventing Herpes Zoster Ophthalmicus (HZO)
por: Aukes, Laurie, et al.
Publicado: (2017)

Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
por: López-Fauqued, Marta, et al.
Publicado: (2017)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods
por: Lin, Kangyang, et al.
Publicado: (2023)

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2010)

Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster
por: van Lier, Alies, et al.
Publicado: (2015)

Varicella and herpes zoster vaccine development: lessons learned
por: Warren-Gash, Charlotte, et al.
Publicado: (2017)

Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine
por: Lu, Tracy J., et al.
Publicado: (2022)

Covid-19 vaccination and possible link to Herpes zoster
por: Lazzaro, D.R., et al.
Publicado: (2022)

COVID-19-vaccine: Herpes zoster: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oupir9sg8kr5jv0ml7eblhfetm